RhumbLine Advisers
SGTX

RhumbLine Advisers’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

RhumbLine Advisers’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-862
Closed -$16K – 3307
2022
Q1 		$16K Buy
862
+21
+2% +$468 ﹤0.01% 3005
2021
Q4 		$30K Buy
+841
New +$47.9K ﹤0.01% 2997

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's SGTX Position: Q2 2022 in Review

RhumbLine Advisers sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 862 shares — an estimated $16K sold.

RhumbLine Advisers first reported a position in SGTX in Q4 2021 and held it in 2 quarters. The position peaked at $30K in Q4 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • RhumbLine Advisers reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 862 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $16K.
  • RhumbLine Advisers first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • RhumbLine Advisers's Sigilon Therapeutics, Inc. Common Stock position peaked at $30K in Q4 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.